DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Drawings
The drawings were received on 4/15/26. These drawings are acceptable.
Specification
The amendment to the specification filed on 4/15/26 has been entered.
The rejections or objections have been overcome by the amendment filed on 4/15/26.
See the reasons for allowance at the end of the office action mailed on 4/15/26.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 4, 5, 24 and 33 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 4 recites the limitation "the transmembrane domain" in line 3. There is insufficient antecedent basis for this limitation in the claim. Claim 3 depends on claim 1 and claim 1 recites at least one transmembrane domain.
Claim 5 recites the limitation "a transmembrane domain" in lines 2-3. There is insufficient antecedent basis for this limitation in the claim. Claim 3 depends on claim 1 and claim 1 recites at least one transmembrane domain.
Claim 24 recites the limitation “a nucleic acid molecule of claim 1" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites: An isolated nucleic acid molecule.
Claim 33 recites the limitation “a nucleic acid molecule of claim 1" in lines 2-3. There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites: An isolated nucleic acid molecule.
Conclusion
Claims 1, 6-8, 10, 12-14, 25, 28-29, 32, 36, and 45-46 are in condition for allowance.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571)272-0764. The examiner can normally be reached on Monday thru Friday; 6:00 AM to 3:00PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil Hammell can be reached at (571)-270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/BRIAN WHITEMAN/ Primary Examiner, Art Unit 1636
Prosecution Insights